medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2002, Number 2

<< Back Next >>

Ann Hepatol 2002; 1 (2)

Dynamics of hepatitis C virus infection

Zeuzem S, Herrmann E

Language: English
References: 59
Page: 56-63
PDF size: 283.27 Kb.


Text Extraction

Viremia shows only minor fluctuations in untreated patients chronically infected with hepatitis C virus. The steady state situation of balanced viral production and clearance in untreated patients can be disturbed by active antiviral treatment. After initiating interferon-a therapy, α typical biphasic decline of viremia can be observed and analyzed. Evaluation of mathematical models of viral dynamics during the initial phase of antiviral treatment shows high turnover rates of pre-treatment viral production and clearance of about 1011 -1013 virions each day and in-vivo half-lives of a few hours for free hepatitis C virions. During the first 24 to 48 hours of therapy, a dose-dependent first phase of interferon-a induced viral kinetics is characterized by a rapid exponential decline of serum viral load. Then viral decline enters a second phase of a relatively slow exponential decay during the following weeks of therapy which mainly reflects the death rate of infected hepatocytes. This second phase decay is predictive for the virologic end-of-treatment and even more the sustained response. Non-responding patients typically show constant viremia or even a rebound during this second phase.


REFERENCES

  1. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK. For the hepatitis interventional therapy group (HIT). Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339: 1485-1492.

  2. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J. For the international hepatitis interventional therapy group (IHIT). Randomized trial of interferon a2b plus ribavirin for 48 weeks or for 24 weeks versus interferon a2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352: 1426-1432.

  3. Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai M-Y, Gane E, O’Grady J, Reichen J, Diago M, Lin A, Hoffman J, Brunda MJ. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343: 1666-1672.

  4. Pawlotsky JM, Bouvier-Alias M, Hezode C, Darthuy F, Remire J, Dhumeaux D. Standardization of hepatitis C virus RNA quantification. Hepatology 2000; 32: 654-659.

  5. Zeuzem S, Franke A, Lee JH, Herrmann G, Rüster B, Roth WK. Phylogenetic analysis of hepatitis C virus isolates and their correlation to viremia, liver function tests, and histology. Hepatology 1996; 24: 1003-1009.

  6. Nguyen TT, Sedghi-Vaziri A, Wilkes LB, Mondala T, Pockros PJ, Lindsay KL, McHutchison JG. Fluctuations in viral load (HCV RNA) are relatively insignificant in untreated patients with chronic HCV infection. J Viral Hepatitis 1996; 3: 75-78.

  7. Yasui K, Okanoue T, Murakami Y, Itoh Y, Minami M, Sakamoto S, Sakamoto M, Nishioji K. Dynamics of hepatitis C viremia following interferon-a administration. J Infect Dis 1998; 177: 1475-1479.

  8. Herz AVM, Bonhoeffer S, Anderson RM, May RM, Nowak MA. Viral dynamics in vivo: limitations on estimates of intracellular delay and virus decay. Proc Natl Acad Sci USA 1996; 93: 7247-7251.

  9. Zeuzem S, Schmidt JM, Lee J-H, Rüster B, Roth WK. Effect of interferon alfa on the dynamics of hepatitis C virus turnover in vivo. Hepatology 1996; 23: 366-371.

  10. Lam NP, Neumann AU, Gretch DR, Wiley TE, Perelson AS, Layden AJ. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology 1997; 26: 226-231.

  11. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, Perelson AS. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-a therapy. Science 1998; 282: 103-107.

  12. Zeuzem S, Schmidt JM, Lee J-H, von Wagner M, Teuber G, Roth WK. Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon alfa on viral turnover. Hepatology 1998; 28: 245-252.

  13. Bekkering FC, Stalgis C, McHutchison JG, Perelson AS. Estimation of early hepatitis C viral clearance in patients receiving daily interferon and ribavirin therapy using a mathematical model. Hepatology 2001; 32: 419-423.

  14. Bekkering FC, Brouwer JT, Leroux-Roels G, van Vlierberghe H, Elewaut A, Schalm SW. Ultrarapid hepatitis C virus clearance by daily high-dose interferon in non-responders to standard therapy. J Hepatol 1998; 28: 960-964.

  15. Bekkering FC, Brouwer JT, Schalm S, Elewaut A. Hepatitis C: viral kinetics [letter]. Hepatology 1997; 26: 1691-1692.

  16. Zeuzem S, Herrmann E, Lee J-H, Fricke J, Neumann AU, Modi M, Colucci G, Roth WK. Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alpha2a. Gastroenterology 2001; 120: 1438-1447.

  17. Neumann AU, Lam NP, Dahari H, Davidian M, Wiley TE, Perelson AS, Layden TJ. Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. J Infect Dis 2000; 182: 28-35.

  18. Shiratori Y, Perelson AS, Weinberger L, Imazeki F, Yokosuka O, Nakata R, Ihori M, Hirota K, Ono N, Kuroda H, Motojima T, Nishigaki M, Omata M. Different turnover rate of hepatitis C virus clearance by different treatment regimen using interferon-beta. J Hepatol 2000; 33: 313-322.

  19. Barouki FM, Witter FR, Griffin DE, Nadler PI, Woods A, Wood DL, Lietman PS. Time course of interferon levels, antiviral state, 2’,5’-oligoadenylate synthetase and side effects in healthy men. J Interferon Res 1987; 7: 29-39.

  20. Wills RJ. Clinical pharmacokinetics of interferons. Clin Pharmacokinet 1990; 19: 390-399.

  21. Nucci ML, Shorr R, Abuchowski A. The therapeutic value of poly (ethylene glycol)-modified proteins. Adv Drug Delivery Rev 1991; 6: 133-151.

  22. Algranati NE, Sy S, Modi M. A branched methoxy 40 kDa polyethylene glycol (PEG) moiety optimizes the pharmacokinetics (PK) of peginterferon a-2a (PEG-IFN) and may explain its enhanced efficacy in chronic hepatitis C (CHC). Hepatology 1999; 30: 190A.

  23. Glue P, Fang JW, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, Salfi M, Jacobs S. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Clin Pharmacol Ther 2000; 68: 556-567.

  24. Lindsay KL, Trepo C, Heintges T, Shiffman ML, Gordon SC, Hoefs JC, Schiff ER, Goodman ZD, Laughlin M, Yao R, Albrecht J. For the hepatitis interventional therapy group. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001; 34: 395-403.

  25. Gilbert BE, Knight V. Biochemistry and clinical applications of ribavirin. Antimicrob Agents Chemother 1986; 30: 201-205.

  26. Di Bisceglie AM, Shindo M, Fong TL, Fried MW, Swain MG, Bergasa NV, Axiotis CA, Waggoner JG, Park Y, Hoofnagle JH. A pilot study of ribavirin therapy for chronic hepatitis C. Hepatology 1992; 16: 649-654.

  27. Di Bisceglie AM, Conjeevaram HS, Fried MW, Sallie R, Park Y, Yurdaydin C, Swain M, Kleiner DE, Mahaney K, Hoofnagle JH. Ribavirin as therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995; 123: 897-903.

  28. Bodenheimer HC Jr, Lindsay KL, Davis GL, Lewis JH, Thung SN, Seeff LB. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology 1997; 26: 473-477.

  29. Lee J-H, von Wagner M, Roth WK, Teuber G, Sarrazin C, Zeuzem S. Effect of ribavirin on virus load and quasispecies distribution in patients infected with hepatitis C virus. J Hepatol 1998; 29: 29-35.

  30. Pawlotsky JM, Dahari H, Conrad A, Lonjon I, Hizode C, Germanidis G, Schmid P, Dhumeaux D, Neumann AU. Effect of intermittent interferon (IFN), daily IFN and IFN plus ribavirin induction therapy on hepatitis C virus (HCV) genotype 1b replication kinetics and clearance. Hepatology 1998; 28: 288A.

  31. Pawlotsky JM, Neumann AU, Conrad A, Hezode C, Lonjon I, Germanidis G, Schmid P, Dhumeaux D. Hepatitis C virus (HCV) dynamics during induction therapy with interferon (IFN) alpha and/or ribavirin. Hepatology 2000; 32: 223A.

  32. Neumann AU, Dahari H, Conrad A, Planko S, McHutchison JG. Early prediction and mechanism of the ribavirin/IFN-a dual therapy effect on chronic hepatitis C virus (HCV). Hepatology 1999; 30: 309A.

  33. Berg T, Kaul T, Naumann U, Wiedenmann B, Hopf, U. Influence of ribavirin on the dynamics of hepatitis C viremia in interferon-a treated patients with response or nonresponse. Z Gastroenterol 2000; 38: 881-886.

  34. Herrmann E, Neumann AU, Schmidt JM, Zeuzem S. Hepatitis C virus kinetics. Antiviral Therapy 2000; 5: 85-90.

  35. Tilg H. New insights into the mechanisms of interferon alfa: an immunoregulatory and anti-inflammatory cytokine. Gastroenterology 1997; 112: 1017-1021.

  36. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. How cells respond to interferons. Annu Rev Biochem 1998; 67: 227-264.

  37. Pawlotsky JM. Hepatitis C virus resistance to antiviral therapy. Hepatology 2000; 32: 889-896.

  38. Sarrazin C, Trojan J, Zeuzem S. Interferons, nucleoside analogs and their actions. Verdauungskrankheiten 2000; 18: 102-113.

  39. Neumann AU, Zeuzem S, Brunda MJ, Hoffman JH. Rapid viral response to treatment with pegylated (40kDa) interferon alfa-2a (PegasysÔ) is strongly predictive of a sustained virologic response in patients with chronic hepatitis C (CHC). Hepatology 2000; 32: 318A.

  40. Yoshioka K, Aiyama T, Okemura A, Takayanagi M, Iwata K, Ishikawa T, Nagai Y, Kakumu S. Humoral immune response to the hypervariable region of hepatitis C virus differs between genotypes 1b and 2a. J Infect Dis 1997; 175: 505-510.

  41. Hattori M, Yoshioka K, Aiyama T, Iwata K, Terazawa Y, Ishigami M, Yano M, Kakumu S. Broadly reactive antibodies to hypervariable region 1 in hepatitis C virus-infected patient sera: relation to viral loads and response to interferon. Hepatology 1998; 27: 1703-1710.

  42. Mondelli MU, Cerino A, Lisa A, Brambilla S, Segagni L, Cividini A, Bissolati M, Missale G, Bellati G, Meola A, Bruniercole B, Nicosia A, Galfre G, Silini E. Antibody responses to hepatitis C virus hypervariable region 1: evidence for cross-reactivity and immune-mediated sequence variation. Hepatology 1999; 30: 537-545.

  43. Brambilla S, Bellati G, Asti M, Lisa A, Candusso ME, D’Amico M, Grassi G, Giacca M, Franchini A, Bruno S, Ideo G, Mondelli MU, Silini EM. Dynamics of hypervariable region 1 variation in hepatitis C virus infection and correlation with clinical and virological features of liver disease. Hepatology 1998; 27: 1678-1686.

  44. Missale G, Cariani E, Lamonaca V, Ravaggi A, Rossini A, Bertoni R, Houghton M, Matsuura Y, Miyamura T, Fiaccadori F, Ferrari C. Effects of interferon treatment on the antiviral T-cell response in hepatitis C virus genotype 1b and genotype 2c infected patients. Hepatology 1997; 26: 792-797.

  45. Fukumoto T, Berg T, Ku Y, Bechstein WO, Knoop M, Lemmens HP, Lobeck H, Hopf U, Neuhaus P. Viral dynamics of hepatitis C early after orthotopic liver transplantation: evidence for rapid turnover of serum virions. Hepatology 1996; 24: 1351-1354.

  46. García-Retortillo M, Forns X, Feliu A, Moitinho E, Costa J, Navasa M, Rimola A, Rodes J. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 2002; 35: 680-687.

  47. Manzin A, Candela M, Solforosi L, Gabrielli A, Clementi M. Dynamics of hepatitis C viremia after plasma exchange. J Hepatol 1999; 31: 389-393.

  48. Ramratnam B, Bonhoeffer S, Binley J, Hurley A, Zhang L, Mittler JE, Markowitz M, Moore JP, Perelson AS, Ho DD. Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis. Lancet 1999; 354: 1782-1785.

  49. Nowak MA, Bonhoeffer S, Hill AM, Boehme R, Thomas HC, McDade H. Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci USA 1996; 93: 4398-4402.

  50. Guidotti LG, Chisari FV. To kill or to cure: options in host defense against viral infection. Curr Opin Immunol 1996; 8: 478-483.

  51. Guidotti LG, Chisari FV. Cytokine-mediated control of viral infections. Virology 2000; 273: 221-227.

  52. Shiffman ML. Use of high-dose interferon in the treatment of chronic hepatitis C. Semin Liver Dis 1999; 19: 25-33.

  53. Carithers RL, Zeuzem S, Manns MP, McHutchison JG, Perrillo RP, Bailey R, Ling M-H, Cohard-Radice M, Albrecht JK. Multicenter, randomized, controlled trial comparing high dose daily induction interferon plus ribavirin versus standard interferon alfa-2b plus ribavirin. Hepatology 2000; 32: 317A.

  54. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht, JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 958-965.

  55. Fried MW, Shiffman ML, Reddy RK, Smith C, Marino G, Goncales F et al. Pegylated (40 kDa) interferon alfa-2a (Pegasys) in combination with ribavirin: efficacy and safety results from a phase III, randomized, actively-controlled, multicenter study. Gastroenterology 2002; 120(suppl 1): A55.

  56. Buti M, Sánchez-Ávila F, Lurie Y, Stalgis C, Valdes A, Martell M, Esteban R . Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin. Hepatology 2002; 35: 930-936.

  57. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon S, Trepo C, Shiffman ML, Zeuzem S, Craxi A, Ling MH, Albrecht J. For the international hepatitis interventional therapy group (IHIT). Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998; 339: 1493-1499.

  58. Hadziyannis SJ, Cheinquer H, Morgan T, Diago M, Jensen DM, Sette H, Ramadori G, Bodenheimer HC, Marcellin P, Lee SD, Roberts PJ, Ackrill AM. Peginterferon alfa-2a (40KD) (Pegasys) in combination with ribavirin (RBV): efficacy and safety results from a phase III, randomized, double-blind, multicentre study examining effect of duration of treatment and RBV dose. J Hepatol 2002; 36(suppl): 3.

  59. Zeuzem S, Lee J-H, Franke A, Rüster B, Prümmer O, Herrmann G, Roth WK. Quantification of the initial decline of serum hepatitis C virus RNA and response to interferon alfa. Hepatology 1998; 27: 1149-1156.




2020     |     www.medigraphic.com